Treatment of graft-versus-host-disease with mesenchymal stromal cells

Cytotherapy

Volumn 13, Issue 3, 2011, Pages 262-268

  Kebriaei, Partow ^a   Robinson, Simon ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL DATA REPOSITORY; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TISSUE REPAIR;

EID: 79951699743     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.549688     Document Type: Review

References (63)

1. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418: 41-9. (Pubitemid 34742565)
2. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for Defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7. (Pubitemid 44269669)
3. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper- Cortenbach I, Marini FC, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7:393-5. (Pubitemid 41671625)
4. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-7. (Pubitemid 29282067)
5. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11-20. (Pubitemid 38019084)
6. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-43. (Pubitemid 34534559)
7. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105: 1815-22. (Pubitemid 40223708)
8. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726-36.
9. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrowderived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol. 2008;251:131-6.
10. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000;28:875-84.
11. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105:93-8. (Pubitemid 34049148)
12. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99:8932-7. (Pubitemid 34693661)
13. Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, et al. Superior ex vivo cord blood expansion following coculture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006;37:359-66. (Pubitemid 43250469)
14. McNiece I, Harrington J, Turney J, Kellner J, Shpall EJ. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy. 2004;6:311-7. (Pubitemid 39214050)
15. Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N, et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton ' s jelly and bone marrow sources. Cell Immunol. 2010;264:171-9.
16. Majore I, Moretti P, Stahl F, Hass R, Kasper C. Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord. Stem Cell Rev. 2010; in press.
17. Najar M, Raicevic G, Boufker HI, Fayyad-Kazan H, De Bruyn C, Meuleman N, et al. Adipose-tissue-derived and Wharton ' s jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A. 2010;16:3537-46.
18. Tong CK, Vellasamy S, Tan BC, Abdullah M, Vidyadaran S, Seow HF, et al. Generation of mesenchymal stem cell from human umbilical cord tissue using a combination of enzymatic and mechanical disassociation method. Cell Biol Int. 2010; in press.
19. Zhang Y, Li C, Jiang X, Zhang S, Wu Y, Liu B, et al. Human placenta-derived mesenchymal progenitor cells support culture expansion of long-term culture-initiating cells from cord blood CD34+ cells. Exp Hematol. 2004;32:657-64. (Pubitemid 38891535)
20. Auletta JJCK, Solchaga LA, Deans RJ, vant Hof W. Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions. Biol Blood Marrow Transplant. 2010;16:891-906.
21. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340-52. (Pubitemid 46674485)
22. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2006;107:1484-90. (Pubitemid 43242385)
23. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-70. (Pubitemid 46697905)
24. Keating A. How do mesenchymal stromal cells suppress T cells? Cell Stem Cell. 2008;2:106-8. (Pubitemid 351168716)
25. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007;92:881-8. (Pubitemid 350144234)
26. Sundin M, Barrett AJ, Ringden O, Uzunel M, Lonnies H, Dackland AL, et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother. 2009; 32:755-64.
27. Li J, Zhu H, Liu Y, Li Q, Lu S, Feng M, et al. Human mesenchymal stem cell transplantation protects against cerebral ischemic injury and upregulates interleukin-10 expression in Macacafascicularis. Brain Res. 2010;1334:65-72.
28. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 2003;101:2999-3001. (Pubitemid 36857986)
29. Chapel A, Bertho JM, Bensidhoum M, Fouillard L, Young RG, Frick J, et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med. 2003;5:1028-38. (Pubitemid 40310427)
30. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004;95:9-20. (Pubitemid 38931831)
31. Prockop DJ, Olson SD. Clinical trials with adult stem/ progenitor cells for tissue repair: let ' s not overlook some essential precautions. Blood. 2007;109:3147-51. (Pubitemid 46572498)
32. Ball L, Bredius R, Lankester A, Schweizer J, van den Heuvel- Eibrink M, Escher H, et al. Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. Leukemia. 2008;22:1256-7. (Pubitemid 351833795)
33. Chung NG, Jeong DC, Park SJ, Choi BO, Cho B, Kim HK, et al. Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int J Hematol. 2004;80:370-6. (Pubitemid 39564640)
34. Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, Levacher B, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graftversus- host disease in mice. J Immunol. 2006;176:7761-7. (Pubitemid 43849077)
35. Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007;21:1992-9. (Pubitemid 47299975)
36. Min CK, Kim BG, Park G, Cho B, Oh IH. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39:637-45. (Pubitemid 46722844)
37. Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, et al. Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy. 2010;12: 361-70.
38. Ye Z, Wang Y, Xie HY, Zheng SS. Immunosuppressive effects of rat mesenchymal stem cells: involvement of CD4+ CD25+ regulatory T cells. Hepatobiliary Pancreat Dis Int. 2008;7: 608-14.
39. Gonzalez-Rey E, Gonzalez MA, Varela N, O' V alle F, Hernandez-Cortes P, Rico L, et al. Human adipose-derived mesenchymal stem cells reduce infl ammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010;69:241-8.
40. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008;181:3933-46.
41. Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol. 2008;36:309-18. (Pubitemid 351221170)
42. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38:1745-55.
43. Croitoru-Lamoury J, Lamoury FM, Zaunders JJ, Veas LA, Brew BJ. Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. J Interferon Cytokine Res. 2007;27:53-64. (Pubitemid 46185062)
44. New JY, Li B, Koh WP, Ng HK, Tan SY, Yap EH, et al. T cell infi ltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant. 2002;29:979-86. (Pubitemid 34845953)
45. Wang L, Li Y, Chen X, Chen J, Gautam SC, Xu Y, et al. MCP-1, MIP-1, IL-8 and ischemic cerebral tissue enhance human bone marrow stromal cell migration in interface culture. Hematology. 2002;7:113-7. (Pubitemid 34692996)
46. Zhang W, Ge W, Li C, You S, Liao L, Han Q, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004;13:263-71. (Pubitemid 38738368)
47. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al. Human mesenchymal stem cells alter antigenpresenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105:2214-9. (Pubitemid 40731815)
48. G ur-Wahnon D, Borovsky Z, Beyth S, Liebergall M, Rachmilewitz J. Contact-dependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. Exp Hematol. 2007;35: 426-33.
49. Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, et al. Bioimaging to monitor the in vivo distribution of infused mesenchymal stem cells: in a mouse model of graft versus host disease. Cell Biol Int. 2010; in press.
50. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. 2001;169:12-20. (Pubitemid 32437040)
51. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-infl ammatory protein TSG-6. Cell Stem Cell. 2009;5:54-63.
52. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graftversus- host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-41. (Pubitemid 38586721)
53. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390-7. (Pubitemid 43847148)
54. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-86. (Pubitemid 351626841)
55. Kurtzberg J, Prasad V, Grimley MS, Horn B, Carpenter PA, Jacobsen D, Prockop S. Allogeneic Human Mesenchymal Stem Cell Therapy (Prochymal) as a Rescue Agent for Severe Treatment Resistant GVHD in Pediatric Patients. Orlando: American Society of Blood and Marrow Transplantation; 2009.
56. von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009;43:245-51.
57. Muller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis. 2008;40:25-32. (Pubitemid 350199635)
58. Fang B, Song Y, Zhao RC, Han Q, Lin Q. Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. Transplant Proc. 2007;39:1710-3. (Pubitemid 46907940)
59. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, et al. efficacy and safety of ex-vivo cultured adult human mesenchymal stem cells (Prochymal (TM)) in pediatric patients with severe refractory acute graft-versushost disease in a compassionate use study. Biol Blood Marrow Transplant. 2010; in press.
60. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15:804-11.
61. Martin BJ, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS, et al. Prochymal Improves Response Rates in Patients with Steroid-Refractory Acute Graft versus Host Disease (SR-GVHD) involving the Liver and Gut: Results of a Randomized, Placebo-Controlled, Multicenter Phase III Trial in GVHD. Orlando: American Society of Bone Marrow Transplantation; 2010.
62. Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graftversus- host disease in a pediatric population. Biol Blood Marrow Transplant. 2010;16:1293-301.
63. Zhou H, Guo M, Bian C, Sun Z, Yang Z, Zeng Y, et al. efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant. 2010;16: 403-12.